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Abstract Case identification is a key component of HIV
prevention efforts; yet rates of HIV testing remain low in
some settings. We explored factors associated with HIV
test avoidance among people who inject drugs (IDU) in
Thailand. Between July and October 2011, 350 Thai IDU
participated in the study. In bivariate analyses, male gen-
der, high intensity drug use, syringe sharing, increased
police presence, and being refused healthcare services were
positively associated with HIV test avoidance, while ever
receiving a hepatitis C test was negatively associated. Our
findings highlight the need for interventions to reduce
stigma in this setting.
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Introduction
Thailand has been the site of a longstanding HIV epidemic
among people who inject drugs (IDU). Of the estimated
160,000 IDU living in Thailand [1], the prevalence of HIV
has consistently remained between 30 and 50 % over two
decades [2]. To reduce the health burden of HIV disease
among this population, many international health organi-
zations are recommending the scale up of HIV testing
services [3, 4]. Previous research has demonstrated that
knowledge of HIV-serostatus has been associated with a
decrease in high-risk behaviours and can lead to more
timely HIV treatment, resulting in reductions in HIV-
related morbidity and mortality, as well as HIV transmis-
sion [5].
In Thailand, HIV testing services are provided through
various means, including in conventional healthcare set-
tings (i.e., hospitals, clinics) and through local and inter-
national non-governmental organizations. However, as a
result of the ongoing criminalization of illicit drug use due
to the 2003 ‘‘War on Drugs’’ campaign and the associated
stigma and discrimination IDU often face within conven-
tional healthcare settings [6, 7], some IDU may be reluctant
to access HIV testing services. More specifically, the
sharing of information on suspected IDU between some
hospitals and police may deter these individuals from
accessing HIV testing through traditional means [6]. As
well, in some voluntary drug treatment centres in Thailand,
HIV testing is mandatory prior to receiving services [3].
Consistently with a 2009 United Nations report, on aver-
age, approximately 20 % of IDU in the Asia–Pacific region
had been previously tested for HIV and were aware of their
serostatus in the last 12 months [4].
Though there are some peer-based HIV testing models
aimed at reducing the stigma associated with injection drug
use and HIV in Thailand, these services are not widespread
throughout the country; HIV testing within traditional
healthcare settings, where there continues to be high dis-
crimination against IDU, is still considered the conventional
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route. In an effort to improve the uptake of HIV testing
among Thai IDU, we sought to explore the prevalence and
correlates of HIV test avoidance among IDU of negative or
unknown HIV serostatus in Bangkok, Thailand.
Methods
Data were derived from the Mitsampan Community
Research Project, a collaborative research project involving
the Mitsampan Harm Reduction Center (MSHRC) (Bang-
kok, Thailand), the Thai AIDS Treatment Action Group
(Bangkok, Thailand), Chulalongkorn University (Bangkok,
Thailand), and the British Columbia Centre for Excellence
in HIV/AIDS (Vancouver, Canada). During July and Octo-
ber 2011, 440 IDU residing in Bangkok or adjacent prov-
inces were recruited into a cross-sectional study through
peer-based outreach efforts and word-of-mouth. Participants
were invited to attend the MSHRC or O-Zone House (drop-
in centres for IDU in Bangkok operated by non-govern-
mental organizations) to be part of the study. Participants
provided oral informed consent and completed an inter-
viewer-administered questionnaire eliciting information
about demographic characteristics, HIV risk and testing
behaviour, and other health-related data. Upon completion
of the questionnaire, participants received a stipend of 350
Thai Baht (approximately $12 USD). The study was
approved by the research ethics boards at Chulalongkorn
University and the University of British Columbia.
For the present analyses, we restricted the study sample
to individuals who were HIV-negative or of unknown HIV
serostatus. We compared the demographic, behavioural,
and social/structural characteristics of IDU who avoid HIV
testing with those who do not using Pearson X2 test.
Fisher’s exact test was used when one or more of the cells
contained values less than or equal to five. For the purpose
of this analysis, HIV test avoidance was measured by
asking participants: ‘‘Do you sometimes avoid accessing
HIV tests because you are a drug user?’’. Demographic
variables considered included: gender (male vs. female)
and median age (C38 years old vs. \38 years old);
behavioural variables included: frequent heroin injection
([weekly vs. Bweekly), frequent midazolam injection
([weekly vs. Bweekly), frequent methamphetamine
injection ([weekly vs. Bweekly), binge drug use (yes vs.
no), syringe sharing (yes vs. no), unprotected sex (yes vs.
no), and ever received a hepatitis C virus (HCV) test;
social/structural variables included: ever incarcerated (yes
vs. no), ever sent to compulsory drug detention centres (yes
vs. no), noticed increased police presence where one buys
or uses drugs (yes vs. no), and ever been refused healthcare
services (yes vs. no). All variables refer to the previous 6
months unless otherwise indicated. IDU who reported ever
being refused healthcare services responded ‘‘yes’’ to the
following question: ‘‘Have you ever had a healthcare
worker refuse to treat you or denied access to medical
treatment or care because you are a drug user?’’ Also,
given the high prevalence of HIV and HCV co-infection
among IDU [8], and that HIV and HCV services are often
delivered together to IDU in many settings, we hypothe-
sized that IDU with a history of HCV testing would be
more willing to access HIV services as well. Thus, we
included the variable ‘‘ever received an HCV test’’ in our
analysis. All p values were two-sided.
Results
In total, 350 IDU with negative or unknown HIV status were
recruited into the study, including 68 (19.4 %) females. The
median age was 38 years (interquartile range: 34–48 years).
In total, 47 (13.4 %) participants reported avoiding HIV
testing. In bivariate analyses, as shown in Table 1, avoiding
HIV testing was positively associated with a number of
demographic and behavioural factors, including: male gen-
der (odds ratio [OR] = 6.27; 95 % confidence interval [CI]:
1.48–26.51), injecting heroin (OR = 2.61; 95 % CI:
1.33–5.13) or midazolam more than once per week
(OR = 2.44; 95 % CI: 1.25–4.73), and having lent or bor-
rowed syringes (OR = 2.19; 95 % CI: 1.07–4.47). Ever
receiving a hepatitis C virus test was negatively associated
with HIV test avoidance (OR = 0.30; 95 % CI: 0.12–0.73).
Additionally, the following social/structural factors were
associated with HIV test avoidance: noticing increased
police presence where one buys or uses drugs (OR = 2.06;
95 % CI: 1.10–3.84), and having been refused treatment or
services by health care workers (OR = 6.72; 95 % CI:
3.06–14.74).
Discussion
We found that many Thai IDU in our study (13.4 %)
reported avoiding HIV testing. Variables significantly and
positively associated with HIV test avoidance included a
diverse set of demographic, behavioural, and social/struc-
tural factors, including: male gender, frequent heroin or
midazolam injection, syringe sharing, noticing police
presence where drugs are bought or used, and having ever
been refused healthcare services. Not surprisingly, IDU
who reported ever having received a HCV test were less
likely to report avoiding HIV testing.
There are various reasons for why IDU may avoid HIV
testing, including: fear of an HIV-positive test result, fear
of being stigmatized and discriminated against by the
community, and feelings of shame [9]. The fact that Thai
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public hospitals register information about active drug
users may also contribute to the reluctance on the part of
IDU to access healthcare [6]. Similarly, prior qualitative
research have also indicated comparable reasons for HIV
test avoidance among other high risk groups, such as
female sex workers and men who have sex with men [10].
Given that to our knowledge, no prior studies have quan-
tified HIV test avoidance among these high risk groups,
Table 1 Bivariate analyses of
demographic, behavioral, and
social/structural factors
associated with avoiding HIV
testing among a community-
recruited IDU in Bangkok,
Thailand (n = 350)
IDU people who inject drugs,
CI confidence interval,
HCV hepatitis C virus
a Activities in the previous 6
months
b Data does not add up to
n = 350 due to missing counts
Avoiding HIV testing
Characteristic Yes 47
(13.4 %)
No 303
(86.6 %)
Odds ratio
(95 % CI)
p value
Demographic variables
Gender
Male 45 (95.7) 237 (78.2) 6.27 (1.48–26.51) \0.01
Female 2 (4.3) 66 (21.8)
Age
C38 years old 24 (51.1) 160 (52.8) 0.93 (0.50–1.72) 0.82
\38 years old 23 (48.9) 143 (47.2)
Behavioural variables
Heroin injectiona
[weekly 16 (34.0) 50 (16.5) 2.61 (1.33–5.13) \0.01
Bweekly 31 (66.0) 253 (84.5)
Midazolam injectiona
[weekly 33 (70.2) 149 (49.2) 2.44 (1.25–4.73) \0.01
Bweekly 14 (29.8) 154 (50.8)
Methamphetamine injectiona
[weekly 6 (12.8) 67 (22.1) 0.52 (0.21–1.27) 0.14
Bweekly 41 (87.2) 236 (77.9)
Binge use
Yes 16 (34.0) 89 (29.4) 1.24 (0.65–2.38) 0.52
No 31 (66.0) 214 (70.6)
Syringe sharinga
Yes 13 (27.7) 45 (14.9) 2.19 (1.07–4.47) 0.03
No 34 (72.3) 258 (85.1)
Unprotected sexa
Yes 16 (34.0) 107 (35.3) 0.95 (0.49–1.81) 0.87
No 31 (66.0) 196 (64.7)
Ever received HCV testb
Yes 6 (12.8) 99 (32.9) 0.30 (0.12–0.73) \0.01
No 41 (87.2) 202 (67.1)
Social/structural variables
Ever incarcerated
Yes 35 (74.5) 215 (71.0) 1.19 (0.59–2.41) 0.62
No 12 (25.5) 88 (29.0)
Ever sent to compulsory drug detention centersb
Yes 12 (26.1) 56 (18.6) 1.54 (0.75–3.17) 0.23
No 34 (73.9) 245 (81.4)
Noticed increased police presence where bought or used drugsa
Yes 27 (57.4) 120 (39.6) 2.06 (1.10–3.84) 0.02
No 20 (42.6) 183 (60.4)
Ever been refused healthcare services
Yes 14 (29.8) 18 (5.9) 6.72 (3.06–14.74) \0.01
No 33 (70.2) 285 (94.1)
2476 AIDS Behav (2013) 17:2474–2478
123
future research should explore and compare the prevalence
of HIV test avoidance among these populations.
A number of demographic and high risk behaviours
were found to be associated with HIV test avoidance. We
found that males were more likely to avoid HIV testing.
This gender difference may reflect the fact that males are
overrepresented in the criminal justice system and conse-
quently more likely to avoid testing services out of fear of
experiencing discrimination related to their engagement in
illegal activities [7, 11]. The finding that participants who
avoid HIV testing were also more likely to engage in
various high risk behaviours, including high intensity drug
use and syringe sharing, is of particular concern. Given that
syringe sharing has shown to be a significant route for HIV
transmission among IDU, and the high prevalence of HIV
among IDU in Thailand [2], novel educational and pro-
grammatic efforts are urgently needed to increase rates of
testing among this high-risk subpopulation of IDU.
We also found that participants who had ever received
HCV testing were less likely to avoid HIV testing. This is
reassuring given that high co-infection rates between HCV
and HIV have been observed among IDU, with a rate as
high as 95 % [8]. However, the fact that more than two-
thirds of participants in our study have never received an
HCV test is of concern. A previous study conducted on
HIV-positive IDU in Bangkok demonstrated that the pri-
mary reason for not accessing HCV testing was that the
participants had ‘‘never heard of HCV’’ [12]. These find-
ings highlight the need for educational and outreach efforts
to increase awareness of and access to both HCV and HIV
testing.
The findings from the present study demonstrate that a
diverse set of social/structural factors increase the likelihood
that IDU will avoid HIV testing. We found that IDU of
negative or unknown HIV-serostatus who reported avoiding
HIV testing were more likely to report being refused treat-
ment or services from healthcare workers. Previous research
has identified that stigmatizing attitudes toward IDU and the
outright denial of health services for IDU persists among
Thai healthcare professionals, and these attitudes may serve
to discourage IDU from further engagement with health
systems, including those that provide HIV testing services
[7]. As well, noticing increased police presence where one
buys or uses drugs was found to be positively associated with
avoiding HIV testing. A large body of evidence demon-
strates the negative health impacts policing practices can
have on the IDU population, yet Thailand continues to rely
on aggressive law enforcement approaches for drug control
[6]. Interventions that aim to reduce stigma and discrimi-
nation against IDU are needed in this setting and other set-
tings like it.
This study has several limitations. First, because of the
cross-sectional nature of the study, we cannot determine a
temporal relationship between exposure and outcome.
Second, the data collected was self-reported and may be
subject to reporting biases. Third, since the study sample
was not randomly selected, the study findings may not be
representative of or generalizable to all Thai IDU or IDU in
other settings. Fourth, given that our data was only able to
determine whether participants avoided accessing HIV
tests due to their drug using behaviour, our analysis was
unable to include information on other reasons why IDU
may avoid HIV testing. Further, we may have underesti-
mated the total proportion of IDU in our study who avoids
HIV testing, as others may avoid testing for other reasons.
Lastly, because of the small sample size, there were wide
intervals around some of the estimates reported.
In summary, we found a high prevalence of HIV test
avoidance among Thai IDU, with males being more likely
to report avoiding HIV testing. Various behavioural fac-
tors, including binge drug use, syringe sharing, and access
to HCV testing, as well as a number of socio-structural
factors, including increased police presence and being
refused healthcare services by healthcare workers, were
also associated with HIV test avoidance. These findings
add further evidence regarding the need for ongoing HIV
prevention education efforts as well as interventions
focused on reducing stigma and discrimination towards
IDU.
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